Global Neuromyelitis Optica Spectrum Disorder Epidemiology Forecast Report 2018-2027

News provided by

Oct 31, 2018, 06:15 ET

DUBLIN, Oct. 31, 2018 /PRNewswire/ --

The "Neuromyelitis Optica Spectrum Disorder (NMOSD) - Epidemiology Forecast-2027" report has been added to ResearchAndMarkets.com's offering.

Neuromyelitis Optica Spectrum Disorder (NMOSD) - Epidemiology Forecast-2027' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of NMOSD in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Neuromyelitis Optica Spectrum Disorder market report gives the thorough understanding of the Neuromyelitis Optica Spectrum Disorder by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Neuromyelitis Optica Spectrum Disorder in the US, Europe, and Japan.

The Neuromyelitis Optica Spectrum Disorder epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report is segmented by prevalent population, gender- specific [Male and Female] and NMO-IgG Diagnosed Cases [NMO-IgG Seropositive and NMO-IgG Seronegative] and Clinical Characterization (Transverse Myelitis, Longitudinally extensive TM, Focal TM, Optic Neuritis, Unilateral ON, and Bilateral ON).

According to this research, the prevalent cases of NMOSD was 32,382 in 2016 in 7 MM and, is expected to increase during the study period i.e., 2016-2027. Among 7MM, United States account for highest prevalent cases of NMOSD with 16,000 prevalent cases in 2016.
Neuromyelitis Optica Spectrum Disorder Epidemiology Segmentation

The report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

The disease epidemiology covered in the report is segmented by prevalent population, gender- specific [Male and Female], NMO-IgG Diagnosed Cases [NMO-IgG Seropositive and NMO-IgG Seronegative] and Clinical Characterization (Transverse Myelitis, Longitudinally extensive TM, Focal TM, Optic Neuritis, Unilateral ON, and Bilateral ON).

Report Scope

The report covers detailed overview of Neuromyelitis Optica Spectrum Disorder explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
The report provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
The Report assesses the disease risk and burden and highlights the unmet needs of Neuromyelitis Optica Spectrum Disorder
The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
The report provides the segmentation of the disease epidemiology by gender and sub-types in 7MM

Key Topics Covered:

1. Key Insights

2. Neuromyelitis Optica Spectrum Disorder: Market Overview at a Glance
2.1. Total Market Share (%) Distribution of Neuromyelitis Optica Spectrum Disorder in 2017
2.2. Total Market Share (%) Distribution of Neuromyelitis Optica Spectrum Disorder in 2027

3. Neuromyelitis Optica Spectrum Disorder: Disease Background and Overview
3.1. Introduction
3.2. Signs and Symptoms
3.3. Clinical features of NMO/NMOSD
3.4. Classification
3.5. Pathogenesis
3.6. Diagnosis
3.7. International consensus diagnostic criteria for Neuromyelitis Optica Spectrum Disorders
3.8. Neuroimaging and neurophysiologic testing
3.8.1. Considerations for AQP4-IgG serologic and another laboratory testing.
3.8.2. Pediatric NMOSD criteria
3.8.3. Monophasic NMOSD
3.8.4. Systemic autoimmunity associated with NMOSD.
3.8.5. Pathology
3.8.6. Opticospinal MS

4. Epidemiology and Patient Population
4.1. Key Findings

5. 7MM Total Prevalent Patient Population of NMO/NMOSD

6. Country Wise-Epidemiology of NMO/NMOSD

7. Market Drivers

8. Market Barriers

9. Appendix

For more information about this report visit https://www.researchandmarkets.com/research/5bp6wm/global?w=5

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets